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Abstract 
Angiocentric glioma is a benign and very rare type of low-grade glioma. Its typical clinical 
presentation is with epileptic seizures, which are usually drug-resistant. The pathogenesis of tumor-
associated seizures is poorly understood. Many possible mechanisms have been implicated, among 
which neurotoxic concentrations of the excitatory neurotransmitter glutamate. Glutamate 
transporters, pyruvate carboxylase and glutamine synthetase are enzymes involved in maintaining 
the physiological concentration of glutamate in the intersynaptic spaces. Specifically, glutamate 
transporters remove glutamate from the synaptic cleft,  pyruvate carboxylase refund the oxidative 
glutamate loss and glutamine synthetase  is involved in the transformation of glutamate into 
glutamine. We studied the immunohistochemical expression of EAAT2 (the most important 
glutamate transporter in the brain), pyruvate carboxylase and glutamine synthetase in a series of 19 
angiocentric gliomas. EAAT2 was never expressed (0%) in the neoplastic cells in any of the cases 
studied. Glutamine synthetase was expressed in the cytoplasm of the neoplastic cells in 17/19 cases 
(89%). Pyruvate carboxylase was diffusely expressed in the cytoplasm of the neoplastic cells in 
18/19 cases (95%). The net result of this enzymatic expression, in particular considering the loss of 
EAAT2, could be an increased glutamate concentration in the synaptic cleft.  Elevated extracellular 
glutamate level might increase local network excitability initially involving intratumoral neurons. 
Despite further studies on larger series are needed, the observation that the angiocentric glioma-
associated epilepsy might be determined from the EAAT2 deficiency open interesting therapeutic 
perspective.  
Introduction 
Angiocentric glioma is a benign and very rare type of low-grade glioma [1]. To date, less than 100 
angiocentic gliomas have been reported. The initial reports date back to 2005 when two 
independent research groups described 18 tumors exhibiting clinic-pathological similarities [2, 3]. 
Angiocentric glioma was included in the 2007 World Health Organization (WHO) Classification of 
Tumors of the Central Nervous System (CNS) and classified as WHO grade I [4]. 
This tumor, which mainly affects children and young adults, develops superficially in the cerebral 
hemispheres most often in the frontal and temporal cortex and less frequently in mid-brain, 
amygdalae and hippocampus [5, 6, 7, 8].  On magnetic resonance imaging (MRI) angiocentric 
gliomas are hyperintense on FLAIR images, non-contrast-enhancing and at times show a band of 
hyperintensity on T1-weighed images. Calcifications are rare. The distinctive histopathological 
characteristics include perivascular arrangement of neoplastic bipolar cells and features of 
ependymal differentiation as evaluated by immunohistochemistry (dot-like positive staining for 
Epithelial Membrane Antigens -EMA- and negative staining for Oligodendrocyte transcription 
factor 2 -OLIG-2-) and by electron microscopy (micro lumens filled with microvilli and ‘zipper-
like’ intermediated junctions). 
An in-frame MYB-QKI gene fusion has been described in this tumor, which is believed to 
contributes to oncogenicity through three mechanisms which include the generation of oncogenic 
MYB-QKI fusion protein, enhancer translocation that establishes an auto regulatory feedback loop 
selectively driving MYB-QKI expression and partial loss of expression of QKI that is a tumor 
suppressor gene [1]. 
The typical clinical presentation is with epileptic seizures, which are usually drug-resistant [9]. It is 
estimated that more than 90% of patients with angiocentric glioma have long-standing epilepsy and 
the morbidity burden of these tumors is more often related to epilepsy than to their neoplastic 
nature. [10]. 
The pathogenesis of tumor-associated seizures is poorly understood. Many possible mechanisms 
have been implicated, among which neurotoxic concentrations of glutamate may play an important 
role. Glutamate, which is crucial for normal brain function, is the main excitatory neurotransmitter 
in the mammalian CNS [12].  Elevated concentrations of extracellular glutamate may determine 
neuronal hyper-excitability and seizures and have been implicated in several other neurological 
disorders including stroke, autism, intellectual disability, amyotrophic lateral sclerosis and 
Alzheimer’s disease. Therefore, in view of the potential neurotoxicity of glutamate, its clearance is 
of great importance. 
In glutamatergic synapses, glutamate is released by pre-synaptic neurons into the synaptic cleft and 
binds to postsynaptic glutamate receptors. Excess of glutamate is removed from the synaptic cleft 
by glutamate transporters mainly present on the astrocytic processes. Into astrocytes glutamate is 
converted into glutamine by glutamine synthetase that catalyzes the ATP-dependent condensation 
of ammonia and glutamate to form glutamine. Subsequently, glutamine is transported back to the 
neuronal presynaptic terminal where it is converted back into glutamate by glutaminase. Thus, 
glutamate-mediated neurotransmission is also based on recycling between the presynaptic axonal 
endings and the surrounding astrocytes. However, during the recycling process a fraction of the 
transmitter pool is lost in oxidative metabolism. This loss is replaced by de novo synthesis, which 
involves the action of astrocytic pyruvate carboxylase [14].  
In order to better understand the pathogenesis of seizures associated with this rare tumor we studied 
the immunohistochemical expression of EAAT2 (the most important astrocytic glutamate 
transporter in the brain), glutamine synthetase and pyruvate carboxylase in a series of 19 
angiocentric gliomas. 
Patients  and  Methods 
Tumor samples were obtained from 19 pediatric patients (age 2–18 years, mean 12 years; 16 boys, 3 
girls) with a histological diagnosis of angiocentric glioma according to the 2016 WHO 
classification of CNS tumors. The commonest localizations were in the frontal, temporal and 
parietal lobe (6, 5 and 5 cases respectively). Two angiocentric gliomas occurred in the 
hippocampus, one in the thalamus and the localization was unknown in the last case.  Data 
concerning symptomatology were known in 9 patients of whom 8 had epileptic seizures. The one 
patient having a thalamic localization of the tumor did not manifest epilepsy. 
Tissue specimens were routinely fixed in 10% buffered neutral formalin, paraffin embedded and 
stained with hematoxilin-eosin (HE) for the morphological evaluation. Five µm sections of the most 
representative paraffin-embedded specimen of each case (specimens in which peritumoral nervous 
tissue was present were preferred) were mounted on electrostatic slides and used for 
immunohistochemistry. As primary antibodies we used Rabbit Polyclonal Anti Human anti-
SLC1A2 [EAAT2] (1:100 dilution; Sigma-Aldrich), mouse monoclonal glutamine syntetase (ready 
to use; Ventana Medical System) and rabbit polyclonal anti human pyruvate carboxylase (1:50 
dilution; Invitrogen) on a Ventana BenchMark ULTRA immunostainer (Ventana Medical Systems). 
The Ventana staining procedure included pretreatment with cell conditioner followed by incubation 
with antibody. The signal, for antibodies, was then developed with ultraView Universal DAB 
Detection Kit. After the staining run was completed, tissue sections were counterstained with 
hematoxylin. We also evaluated the EAAT2, glutamine synthetase and pyruvate carboxylase 
expression in peritumoral non neoplastic tissue, of at all present. 
  
Results 
Peritumoral tissue was included in 14 slides immunostained with EAAT2 and in 15 slides 
immunostained  with glutamine syntetase and pyruvate carboxylase. 
EAAT2 was never expressed (0%) in the neoplastic cells in any of the cases studied. Cytoplasmic 
immunostaining was present in the intralesional and perilesional astrocytes. 
Pyruvate carboxylase was diffusely expressed in the cytoplasm in 18/19 cases (95%). A 
cytoplasmic immunostaining was present in the intralesional and perilesional astrocytes. 
Glutamine synthetase was expressed in the cytoplasm of the neoplastic cells in 17/19 cases (89%; 






Glutamate is a non-essential aminoacid that acts as either a powerful excitatory neurotransmitter or 
potent signaling molecule playing an important role in synaptogenesis, cellular metabolism, 
migration, differentiation and death and intervening in higher order brain functions such as learning 
and memory. Excess of glutamate is associated with the initiation, spread and maintenance of 
seizure activity. High glutamate concentration is neurotoxic and consequently its homeostasis is 
important. Glutamate transporters, pyruvate carboxylase and glutamine synthetase are involved in 
maintaining the physiological concentration of glutamate in the intersynaptic spaces. 
Glutamate transporters, present in both neurons and glial cells, are crucial to remove the glutamate 
from the synaptic cleft and maintaining low extracellular concentrations to prevent aberrant 
glutamate signaling. There are different families of glutamate transporters, among which the NA+-
dependent Excitatory Amino Acid Transporter (EAAT) which consists of five Na+dependent high-
affinity glutamate transporters progressively designated as EAAT1 to EAAT5. EAAT2 (also known 
as Glutamate Tansporter-1 -GLT1-) is a predominantly glial glutamate transporter and is 
responsible for 95% of total forebrain glutamate uptake activity. [17]. 
Pyruvate carboxylase is a biotin containing anaplerotic enzyme that converts pyruvate to 
oxaloacetate for entry into the tri-carboxylic acid (TCA) cycle. It is expressed in several tissues with 
highest activity in liver, kidney, adipose tissues, mammary gland, and pancreatic islets, moderate 
activity in brain, heart, and adrenal gland, and low activity in white blood cells and skin fibroblasts. 
Pyruvate carboxylase plays a crucial role in intermediary metabolism, controlling fuel partitioning 
toward gluconeogenesis, lipogenesis, glucose-induced insulin secretion and in the biosynthesis of 
neurotransmitters. Its role is particularly important for the de novo synthesis of glutamate which is 
crucial in compensating for the catabolism of glutamate. Indeed, pyruvate carboxylase refund the 
oxidative glutamate loss via oxaloacetate-TCA cycle-α-ketoglutarate. α-ketoglutarate can in turn be 
converted to glutamate via glutamate dehydrogenase. In CNS it has been shown to be expressed in 
astrocytes. 
Glutamine synthetase participates to several important metabolic pathways. In humans it is 
abundantly present in a limited set of hepatocytes surrounding the terminal hepatic veins and in 
skeletal muscle cells. It is also expressed in astrocytes, close to vascular structures and excitatory 
synapses. In the CNS glutamine synthetase participates in the detoxification of blood-derived and 
metabolically generated brain ammonia and in the synthesis and re-cyclization of neurotransmitters. 
In particular it is involved in the transformation of glutamate into glutamine (which in turn acts as a 
substrate for the new synthesis of glutamate through the neuronal enzyme glutaminase), but it is 
also the main precursor for the biosynthesis of the inhibitor neurotransmitter GABA. 
Considering that loss of EAAT2 causes glutamate accumulation in the synaptic cleft, that pyruvate 
carboxylase activity results in glutamate synthesis, and that loss of glutamine synthetase causes a 
reduced conversion of glutamate in glutamine, it is conceivable that an altered expression of these 
enzyme could determine hyper-excitability and epilepsy in both non-neoplastic and neoplastic 
conditions. Several studies confirm this hypothesis. 
Deletion of the EAAT2 gene in mice causes nearly complete loss of glutamate uptake activity and 
seizures while at opposite transgenic mice overexpressing EAAT2 are less prone to acute status 
epilecticus, exhibiting attenuated epileptogenesis and reduced seizures. Recent researches in the 
human have suggested that de novo mutations in EAAT2 may determine early-onset epilepsy with 
multiple seizure types and that dysplastic cortical tissue has a reduced expression in EAAT2 
protein. It has been demonstrated that gliomas associated with seizures have significantly higher 
glutamate levels and reduced expression of transporters (in particular EAAT2) both within the 
tumor and in peritumoral regions. The mechanisms whereby neoplastic astrocytes silence their 
EAAT2 expression remain to be defined.  A possible epigenetic regulation of EAAT2 transcription 
based on the methylation of the corresponding promoter and the expression of aberrant EAAT2 
mRNA have been postulated. However, whatever the cause for absent or reduced EAAT2 
expression in gliomas, it would seems that the consequent high glutamate concentration plays an 
important role in tumor-associated seizures. Consequently, an induced increased EAAT2 protein 
expression might represent a potential therapeutic approach for treating tumoral associated epilepsy. 
Pyruvate carboxylase is implicated in several pathological conditions such as cancers including 
gliomas and pyruvate carboxylase deficiency disorders. In glioblastoma, up-regulation of pyruvate 
carboxylase enables glutamine-independent growth of wild-type isocitrate dehydrogenase 1 (IDH1) 
glioblastoma cells suggesting that this enzyme can serve as a metabolic alternative to glutamine. 
There are 3 type of pyruvate carboxylase deficiencies named A, B and C. In the more severe forms 
different CNS lesions have been described (i.e. subdural effusion, ischemia-like, periventricular 
hemorrhagic cysts, cerebral atrophy and delayed myelination) some of which are potentially 
epileptogenic.  Furthermore, in affected patients epilepsy might be related to energy dysfunction 
secondary to defective Krebs cycle. 
Glutamine synthetase is an astrocytic enzyme with putative antiepileptic activity as it catalyzes the 
conversion of glutamate and ammonia to glutamine. Glutamine synthetase is also one of the main 
sources of carbon and energy in many cancers and it has been noted that the administration of 
glutamine increases cell proliferation [25, 26]. In astrocytomas an inverse correlation between 
glutamine synthetase expression and epilepsy and adverse prognosis has been documented.  
No studies specifically investigated the EAAT2, pyruvate carboxylase and glutamine synthetase 
expression in angiocentric gliomas in spite of a number of researches highlighted the role of a 
deregulated expression of these enzyme in the pathogenesis of tumor-associated   epilepsy. 
All angiocentric gliomas we studied lack EAAT2 expression while pyruvate carboxylase and 
glutamine synthetase expression are mostly preserved. Despite the preserved expression of 
glutamine synthetase in neoplastic cells, the net result could be an increased glutamate 
concentration in the synaptic cleft.  Elevated extracellular glutamate level might increase local 
network excitability initially involving intratumoral neurons.  
The hypothesis that the angiocentric glioma-associated epilepsy is determined from the EAAT2 
deficiency might open interesting therapeutic perspective. Several studies emphasized the 
possibility to pharmacologically  raise the EAAT2 levels. 
In conclusion, our results show that angiocentric glioma cells loss EAAT expression and suggest 
that the main clinical consequence of this tumor might derive from deficient EAAT2 expression.  
Further studies on larger series are necessary to confirm this hypothesis.  
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